http://www.send2press.com/newswire/ Business, Entertainment and Technology News Sat, 11 Feb 2012 15:19:40 GMT http://neotrope.com 60 en-us 144 31 http://www.send2press.com/newswire/index.shtml http://www.send2press.com/XML/send2press-rss.gif http://www.send2press.com/newswire/2012-02-0203-003.shtml Fri, 03 Feb 2012 18:33:32 GMT Business Medical Houston Texas Send2Press Newswire http://www.send2press.com/newswire/2012-02-0203-003.shtml TeDan Surgical Innovations HOUSTON, Texas, Feb. 3, 2012 (SEND2PRESS NEWSWIRE) -- TeDan Surgical Innovations, industry leader in surgical access instrumentation, announces the launch of the Phantom Series MIS Anterior Hip Retractor System. TeDan Surgical's revolutionary hip retractor utilizes a system of adjustable surgical arms with attachable retractors, enabling surgeons to perform the entire procedure without a fracture table or a surgical assistant.

Dr. Lawrence Menendez and Dr. Daniel Allison, Orthopedic Surgeons at the University of Southern California Medical Center, partnered with TeDan Surgical to design and develop this innovative retractor.

Dr. Allison shared their idea with the TSI team. "We wanted to create a system that could place the anterior approach to hip replacement into the hands of any orthopedic surgeon, minimizing trauma to the patient's soft tissues and bone, while taking away the need for any surgical assistants."

The Phantom Series MIS Anterior Hip Retractor System has been used in surgery over twenty times. Evaluations by surgeons have deemed the system a success.

According to Dr. Menendez, initial trials exceeded expectations. "We were nervous before the first surgery that things wouldn't come together or the surgery would become more complicated, but from the first go-round, the surgery was made much easier. Since then we've only been making it better. We set some lofty goals and feel like we've accomplished them. We are very excited to start giving this system to other surgeons and patients."

With the realization that performing hip replacements through the anterior approach may expedite patient recovery time and reduce post-operative discomfort, surgeons, with increasing frequency, are opting to operate using the anterior technique. Previously, this technically demanding approach has only been possible using a Judet style fracture table and two surgical assistants. The Phantom MIS Anterior Hip Retractor System allows surgeons to access the surgical site through the anterior approach on a standard operating table without a fracture table or additional personnel.

About TeDan Surgical Innovations:
Founded in 2006 with the goal to innovate existing retraction techniques, TeDan Surgical has become an industry leader in access instrumentation. TeDan's patented retractors increase visibility for surgeons while decreasing patient wound size and the potential for tissue trauma. Experience the difference. Experience Innovation.

To learn how to maintain operative independence contact:
TeDan Surgical Innovations
+1-713-726-0886
hipretractor@tedansurgical.com.
http://www.tedansurgical.com .

- 300dpi logo download for media:
http://Send2Press.com/mediaboom/12-0203-tedan_300dpi.jpg .

NEWS SOURCE: TeDan Surgical Innovations
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2012 Neotrope® News Network - all rights reserved.

TAGS: TeDan Surgical Innovations, Devices and Research, Send2Press. ]]> http://www.send2press.com/newswire/2012-01-0109-001.shtml Mon, 09 Jan 2012 05:58:29 GMT Science Legal and Law Washington District of Columbia Send2Press Newswire http://www.send2press.com/newswire/2012-01-0109-001.shtml Dr. David Lewis WASHINGTON, D.C., Jan. 9, 2012 (SEND2PRESS NEWSWIRE) -- Dr. David Lewis, internationally known whistleblower and respected expert on institutional fraud, released a report today calling for a formal investigation into the practices of the British Medical Journal (BMJ), and specifically into the actions of its editor, Dr. Fiona Godlee, and Brian Deer, a reporter she hired to write a series of articles which appeared in the journal beginning on January 4, 2011.

The BMJ articles accuse Dr. Andrew Wakefield of committing scientific fraud in a 1998 Lancet publication - http://www.thelancet.com/journals/lancet/article/PIIS0140673697110960/fulltext - he co-authored that brought global attention to a link many parents and physicians suspect may exist between autism and children who are genetically predisposed to adverse reactions from the Measles/Mumps/Rubella (MMR) vaccine.

The BMJ, Deer, and Godlee alleged that Wakefield fabricated a diagnosis of colitis in most of the 12 children described in The Lancet article - calling Wakefield's work an "elaborate fraud" intended to create an "MMR scare" - so Wakefield could profit from a patent related to his research.

"Documents recovered from Dr. Wakefield's files during my investigation at the National Whistleblowers Center (NWC) - www.researchmisconduct.org - reveal that a pathologist associated with the study, Dr. Andrew Anthony, interpreted a number of the children's biopsies as evidence of colitis," explained Dr. Lewis. "Altogether, the evidence contained in Wakefield's files suggested to me that the BMJ's fraud theory was more tabloid news than science."

According to documents Lewis filed with Sir John Tooke, Vice-Provost for Health at the University College London (UCL) where The Lancet study was done, BMJ Editor Godlee responded to the Lewis revelations by "cherry-picking the evidence and coming up with a grand conspiracy theory involving 'institutional research misconduct'. Alleged fraudsters now include University College London (UCL) administrators, the Royal Free Hospital, and all 13 co-authors of the Lancet study."

UCL President Malcolm Grant notified Lewis that, because his charges were "so serious," he urged Dr. Lewis to inform Dr. Godlee and Deer "at the earliest opportunity."

Lewis also reports that Godlee has previously acknowledged the BMJ Group receives funding from the two manufacturers of the MMR vaccine, Merck and GlaxoSmithKline, and has testified in a Parliamentary inquiry that peer-reviewed medical journals are "the marketing arm of the pharmaceutical industry." Lewis added: "Apparently scientists who question certain government policies and industry practices can be destroyed for a price. If so, this kind of tabloid science poses a genuine threat to public health."

On January 3, 2012, Dr. Wakefield filed suit against the BMJ and Brian Deer ( http://www.courthousenews.com/2012/01/04/BritMedJ.pdf ). Last September, Columbia University published a major study supporting the link Dr. Wakefield established between autism and enterocolitis ( http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174969/ ).

Lewis Investigation Available Online:
Dr. Lewis' detailed investigation of the BMJ series in question can be downloaded from the following URL provided by his attorneys at Hallman & Wingate, LLC:

http://www.hallmanwingate.com/fullpanel/uploads/files/david-lewis-bmj.pdf .

About Dr. David Lewis:
Dr. David Lewis, a member of the NWC Board of Directors and Director of its Research Misconduct Project, is a former senior-level research microbiologist for the U.S. Environmental Protection Agency (EPA). He was the only EPA scientist to ever publish first-authored research articles in Lancet and Nature. His research published in Lancet and Nature Medicine on the inadequacy of CDC guidelines to prevent transmission of HIV in dentistry prompted the current heat sterilization standard for dentistry in the mid-1990s. His environmental research published in Nature received the Science Achievement Award by the EPA Administrator in 2000. Editors at Annals of Internal Medicine rated him in the top 10 percent of reviewers in 2010. His accomplishments in medical and environmental research have been widely covered in professional, scientific and popular publications and broadcasts including Nature, Science, Lancet, JAMA, National Geographic, Reader's Digest, Voice of America, Paul Harvey News, Time, Newsweek, U.S. News & World Report, Forbes, NY Times, Washington Post, London Times, NPR's All Things Considered, PBS Healthweek, PBS Technopolitics, CBS Evening News, ABC's Primetime Live, and BBC Panorama.

Dr. Lewis's direct contact information: (706) 296 3675, LewisDaveL@aol.com .

About the BMJ:
The British Medical Journal is a highly regarded, peer-reviewed scientific journal. BMJ is sent to more than 100,000 doctors internationally, many of whom have stakes in vaccine usage.

Media Contact:
Elizabeth Horn
Horn Productions
650-685-0435
elizabeth@hornproductions.net .

NEWS SOURCE: Dr. David Lewis
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2012 Neotrope® News Network - all rights reserved.

TAGS: Dr. David Lewis, Devices and Research, Send2Press. ]]> http://www.send2press.com/newswire/2011-12-1212-002.shtml Mon, 12 Dec 2011 15:13:12 GMT Computing Internet Bethesda Maryland Send2Press Newswire http://www.send2press.com/newswire/2011-12-1212-002.shtml M-3 Information BETHESDA, Md., Dec. 12, 2011 (SEND2PRESS NEWSWIRE) -- M3 congratulates David Grant PhD and his team at the UCLA Center for Health Policy Research for their landmark November 2011 study outlining California's unmet Mental Health needs. Consistent with an earlier nationwide survey, this new study found that only half of Californians with mental illness receive treatment, while just one in four receives adequate treatment.

Review study at (PDF): healthpolicy.ucla.edu/pubs/files/MentalHealthreportnov2011.pdf .

Recent nationwide healthcare reform supports screening by mandating coverage, including the elimination of co-pays, for adult depression screening in doctors' offices. As a state-of-the-art multi-dimensional screen designed to fit this role, the M3's validity was demonstrated in the March 2010 Annals of Family Medicine.

Fostering office-centered patient engagement in accord with the Medical Home model, M3 offers clinicians a web-based portal for screening and longitudinal tracking of progress for these conditions, while fulfilling criteria for physician reimbursement. Cloud-based and HIPAA-compliant, M3Clinician.com requires no investment in software or hardware. Compatible with the Apple iPad and other similar devices, this game-changing option maximizes clinical engagement with the patient by providing efficient clinical decision support at the point of care. The M3 provides a total score, measuring the overall symptom burden, while four subscores indicate specific risks for depression, anxiety, PTSD and bipolar disorders.

The M3 offers this same powerful tool to large managed care plans and individual practices, and the reports generated are readily incorporated into most Electronic Health Record systems.

Fortunately, individuals with mental illness can find support at mymoodmonitor.com, where M3 provides, in English and Spanish, a free confidential screen for mood and anxiety disorders. The free screen can also be found, along with other valuable resources, at Mental Health America's website. Many people are aware of how common depression is, yet do not realize anxiety disorders are even more prevalent, and that bipolar disorder is often overlooked or misdiagnosed. The National Institute of Mental Health, through its sponsorship of the Grand Challenges of Global Mental Health, listed as the first of its 25 challenges to "integrate screening and core packages of services into routine primary health care." Armed with an understanding of mood and anxiety symptoms, individuals are more likely to actively engage in the effective treatments that are available. The new California study once again demonstrates how mental illness can worsen or complicate other chronic physical conditions, like diabetes, heart disease and high blood pressure, and increase the risk for obesity and tobacco and alcohol dependence.

An instructional video demonstrating the M3 screen can be found on YouTube at http://www.youtube.com/watch?v=gdBTCtosSIs&layer_token=b3b8c6b68e61ac4d .

About M3: M3 is based in Bethesda, Maryland. M3 is dedicated to improving the recognition and treatment of mental illness within primary care. Visit M3 on Facebook and at iTunes. Developer Information.

NEWS SOURCE: M-3 Information
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2011 Neotrope® News Network - all rights reserved.

TAGS: M-3 Information, Devices and Research, Send2Press. ]]> http://www.send2press.com/newswire/2011-10-1031-001.shtml Mon, 31 Oct 2011 03:57:54 GMT Medical Pharma Malvern Pennsylvania Send2Press Newswire http://www.send2press.com/newswire/2011-10-1031-001.shtml Reaction Biology Corporation MALVERN, Pa., Oct. 31, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ("RBC") today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC's proprietary HotSpot(SM) technology.

The paper, "Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity," was the product of a collaboration between RBC and the Fox Chase Cancer Center of Philadelphia. The article is currently available online and will be in the November 2011 print edition of Nature Biotechnology.

The data set from the study can be viewed at reactionbiology.com/webapps/kir/.

To perform the study, the researchers selected 178 small molecule kinase inhibitors, including FDA-approved drugs, clinical trial agents and research compounds. These compounds, known to include inhibitors of all major kinase families, were then systematically profiled against 300 human wild-type kinases, also representing all major kinase families. Quantitative analysis of the results revealed that many well-studied kinase inhibitors had significant and hitherto unknown off-target activities. In other words, not only did they inhibit enzymes belonging to the same subfamilies as their putative targets, but they also inhibited kinases from completely different families. 6 compounds, in particular, had off-target inhibition levels stronger than the intended target. These results emphasize the importance of profiling compounds against a broad kinase panel before proceeding to animal studies or clinical trials.

As part of their analysis of the new data set, the authors introduced the concept of a "uni-specific kinase inhibitor." A compound with a high "uni-specificity" score is one whose inhibition of one particular kinase greatly exceeds its inhibition of the second most inhibited kinase, a stringent measure of compound selectivity. This approach helped to identify many potential lead compounds for "orphan" kinases, enzymes for which few inhibitors currently exist. In a parallel analysis of the data set, the researchers sought compounds whose primary target was a cancer-relevant kinase, but which could also inhibit a limited number of cancer-relevant kinases outside the primary target's family. Such an approach can serve as the starting point for developing new multi-targeted kinase inhibitors and therapeutics.

"Kinase drug discovery remains a significant interest for both our academic customers and those in the pharmaceutical industry," said Haiching Ma, Ph.D., Chief Technology Officer of RBC and one of the lead authors. "In the past decade, a large number of kinase inhibitors have been synthesized and published. However, there is no study trying to understand how these compounds interact with a large panel of kinases, especially using the activity-based assay formats used by majority of the kinase research labs. Applying the low-cost, high-throughput HotSpot platform, RBC has created the most reliable kinome-inhibitor database that a 'gold standard' radiometric assay format can produce."

Dr. Ma continued, "This data set will not only help drug discovery activity in the industry, but also provide guidance for selecting the right tool compounds for use in routine kinase biology studies. RBC's HotSpot provides a vital tool to evaluate these potential drug candidates."

To date, RBC has developed and optimized assays for over 400 human kinases, including atypical kinases, mutants and lipid kinases that are important drug targets. "RBC is the market leader in providing activity-based screening and profiling. The panel we have collected has 100 more enzymes than most of our competitors," said Mr. Matthew Oristano, Chairman of RBC. "With this continually growing panel of kinases, we can offer scientists a better understanding of their compounds and reduce the failure rate in future clinical trials. This publication has clearly demonstrated the value of including kinome-wide profiling as an integral part of compound lead validation."

About Reaction Biology Corp.:
Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services. With over 400 kinases, RBC's coverage of the kinome is the broadest in the industry for enzyme activity assays. Using its proprietary HotSpot(SM) technology and other innovations, RBC is also expanding its services to cover a broad range of epigenetic regulatory enzymes, including HDACs, HATs, HMTs, DNMTs, demethylases and epigenetic readers. RBC provides its services to over 200 customers worldwide, including large pharmaceutical, biotech, government and academic labs.

For more information, visit: www.reactionbiology.com.

HotSpot is a service mark of Reaction Biology Corp.

NEWS SOURCE: Reaction Biology Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2011 Neotrope® News Network - all rights reserved.

TAGS: Reaction Biology Corporation, Drugs and Pharmaceuticals, Send2Press. ]]> http://www.send2press.com/newswire/2011-10-1004-009.shtml Tue, 04 Oct 2011 20:47:39 GMT Computing Medical Waterloo Ontario, Canada Send2Press Newswire http://www.send2press.com/newswire/2011-10-1004-009.shtml RoweBots Research Inc. WATERLOO, Canada, Oct. 4, 2011 (SEND2PRESS NEWSWIRE) -- RoweBots Inc., the leading supplier of tiny embedded Linux-compatible real-time operating systems (RTOS) products, today announced that the Unison™ Operating System (OS) is a core component in a variety of medical equipment. The Unison OS controls operating room equipment, intelligent eyewear and other advanced medical devices for the home, physician's offices and hospitals.

The launch and release of Unison OS, Version 5.2 along with the Xilinx Microblaze softcore made this technology possible. Unison provides the key, high-performance software framework required. The Unison ultra-tiny embedded Linux-compatible RTOS opens a broad set of medical, embedded or imaging applications to Linux- and POSIX-compatible development with extensive connectivity options, data storage and substantially enhanced performance on the same hardware.

John Soloninka from HTX, one of Canada's leading medical research organizations had this to say: "HTX saw great value in RoweBots. This collaboration produced the next generation of embedded microprocessors. Xilinx combined with the powerful Unison embedded operating system reduces the cost and time to produce more powerful medical devices."

Unison's open standards or Linux compatibility, ultra tiny size, zero boot time, high performance and modularity are the key features which substantially reduce system development risk, cost and time. Over 50 Unison demonstration programs run out of the box on Xilinx Microblaze development kits in 10 minutes.

Using Unison Version 5.2, you get instant results. Unison's newest features include:
* USB host and device I/O (http://rowebots.com/embedded_system_software/usb_stack )

* Extensive wireless I/O (http://rowebots.com/embedded_system_software/wireless_protocols )
- 6loWPAN
- 802.15.4 SimpliciTI
- Bluetooth

* Enhanced networking
- TCP IPv6 with IPv4 (http://rowebots.com/Embedded_System_Software/TCP_IP_Stack )
- SNMP v1, 2c, 3 (http://rowebots.com/embedded_system_software/networking_protocols )

* Compact Flash File system (http://rowebots.com/Embedded_System_Software/Embedded_file_system )

* High performance PCIe

* Graphics (http://www.rowebots.com/embedded_system_software/graphics )

* Remedy Tools
- RED Analyzer (http://rowebots.com/embedded_software_development/remedy_red_analyzer )
- Bootloader (http://www.rowebots.com/embedded_software_development/remedy_bootloader )

See the video here: http://www.youtube.com/watch?v=d5ata2rdzOw .

Unison V5.2 and V4.2 are shipping. Commercial licenses for Unison OS with serial I/O and a file system start at $999 USD.

About Xilinx:
Xilinx is the world leader in FPGAs.

About RoweBots Research Inc.:
RoweBots is developing the next generation of modular system on chip ultra tiny embedded Linux software for embedded OEM applications For more information, visit the RoweBots web site www.rowebots.com.

Trademarks: Unison is a registered trademark of RoweBots Research Inc. All other product and company names are the trademarks of their respective owners.

- Image Caption: Unison OS 5.2 provides an ultra tiny POSIX operating system on the Xilinx Microblaze softcore with extensive I/O options including high performance PCIe and USB.

NEWS SOURCE: RoweBots Research Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2011 Neotrope® News Network - all rights reserved.

TAGS: RoweBots Research Inc., Software, Send2Press. ]]> http://www.send2press.com/newswire/2011-09-0915-001.shtml Thu, 15 Sep 2011 19:08:07 GMT Business Internet Houston Texas Send2Press Newswire http://www.send2press.com/newswire/2011-09-0915-001.shtml TeDan Surgical Innovations HOUSTON, Texas, Sept. 15, 2011 (SEND2PRESS NEWSWIRE) -- TeDan Surgical Innovations is proud to announce the launch of its redesigned website. The new website provides detailed product information on all of TeDan's surgical retractors and corresponding instrumentation. Site visitors can access over 2,000 TeDan product pages using new navigational tools at www.tedansurgical.com .

Among the site's features, the "Literature" page offers users the ability to download all of TeDan's publications, including brochures, catalogs, and instructions for use. To keep up with TSI on the road, visitors can view future trade show dates, locations, and booth numbers under the "Events" page. An advanced search tool allows TeDan products to be cross referenced with competitor products.

Approved distributors have the ability to view list prices and generate printable, PDF quotes through the website. A detailed PDF version of the quote includes colored product pictures and itemized pricing. If distributors prefer, the quote logo and address can be easily customized to meet the needs of the distribution company. All generated quotes are automatically saved, and can be accessed and modified at any time.

The website redesign features vibrant colors and sharp images, creating an enjoyable experience for website navigators. For more information regarding TeDan's Surgical Products, please contact us at: www.tedansurgical.com/contactus .

About TeDan Surgical Innovations:
TeDan Surgical Innovations was founded in 2006 with the goal to innovate and address evolving surgical techniques in spine surgery. We have successfully addressed the need for minimally invasive, posterior, lateral and anterior surgical approaches to the spine, and have become a leader in the industry by providing high quality state-of-the-art surgical devices that address customer and market needs, on time, and to comply with requirements and maintain the effectiveness of the quality management system.

Based in Houston, Texas, TeDan Surgical Innovations supplies durable and effective surgical instruments for accessing the spine to hospitals nationwide and around the world. Our experienced product engineer works closely with surgeons to create new products that meet the ever-evolving challenges of the operating room. We are proud to hold patents for our retractors that use innovative designs to increase visibility for surgeons while decreasing patient wound size and the potential for tissue trauma. Experience the difference. Experience innovation.

Follow TeDan Surgical Innovations on Facebook.

NEWS SOURCE: TeDan Surgical Innovations
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2011 Neotrope® News Network - all rights reserved.

TAGS: TeDan Surgical Innovations, Devices and Research, Send2Press. ]]> http://www.send2press.com/newswire/2011-06-0622-003-Social-Entrepreneur.shtml Wed, 22 Jun 2011 19:36:38 GMT Awards and Honors NonProfit Minneapolis Minnesota Send2Press Newswire http://www.send2press.com/newswire/2011-06-0622-003-Social-Entrepreneur.shtml DesignWise Medical Inc MINNEAPOLIS, Minn., June 22, 2011 (SEND2PRESS NEWSWIRE) -- DesignWise Medical (www.designwisemedical.org), a nonprofit pediatric medical device organization and recent runner-up in the Mosaic Social Entrepreneurs Cup competition, announced today that it has added four new members to its board of directors. With the addition of Gwenyth Fischer MD, James Davenport, Al Emola and Phil Kading, the DesignWise Medical board has grown to nine members, joining current board members Jodi Raus, Jim Hartman, Ann Johnson, Tom McGoldrick and Brad Slaker.

"DesignWise Medical is blazing a new path in social entrepreneurship as a non-profit medical device company and this can only be accomplished through the skills, experience and energy of our board of directors. The additions of Gwenyth, James, Al and Phil add to the breadth of experience and functional expertise of our board. I am more confident than ever that we will be successful in our efforts to bring needed products to children that will improve their health and quality of life," said DesignWise Medical founder and CEO Brad Slaker.

One of the main activities of the board is the implementation of DesignWise Medical's Charter Campaign, a sponsorship opportunity for individuals and organizations to provide financial support to DesignWise Medical and be permanently recognized as foundational partners. Individual project sponsorship opportunities also are available.

Dr. Fischer is a board certified pediatrician and 2010 Medical Device Center Innovation Fellow at the University of Minnesota, where she is completing a clinical fellowship in pediatric critical care. Fischer is a co-founder and Associate Director of Pediatric Innovation with the Minnesota Pediatric Devices Consortia, which will be actively developing and promoting pediatric specific technology starting in the fall of 2011. She received her bachelor's degree at Vassar College in New York with a focus in cognitive sciences, and received her medical degree from Loyola University in Chicago. She completed a pediatric residency at Children's Hospital at Dartmouth before returning to Minnesota.

James Davenport is a partner with KPMG LLP and serves as the firm's healthcare leader in the Upper Midwest. He serves clients in the payer, provider and medical technology sectors and is responsible for KPMG's service strategy and delivery to this market. Davenport also serves on KPMG's national leadership team for the managed care sector and authors an annual Managed Care Industry report that is distributed nationally. In addition to his professional work in healthcare, Davenport is the proud father of a daughter who spent three months in the neonatal intensive care unit and was the beneficiary of a number of pediatric medical devices. He also serves as the vice-chair of the Boys and Girls Clubs of the Twin Cities and is a member of the Neonatal Experience Team at Children's Hospital and Clinics of Minnesota.

Al Emola has been in the healthcare industry for over 30 years and has served as president and CEO of several companies, including StentTech, Vital Images and FlexMedics. Emola began his career in marketing at Bristol-Myers/Squibb followed by marketing, strategic planning and business development positions at American Hospital Supply Corporation and St. Jude Medical. He has served on the boards of Vital Images, StentTech, Medafor and Enpath Medical. He holds an MBA from Indiana University's Kelley School of Business and is currently consulting with medical device start-ups and turnarounds.

Phil Kading is the Client Strategy Director for OptumHealth's Innovation Health Solutions group. Kading is responsible for delivering client performance reporting, client support, development of strategic client road maps, and driving innovative solutions in the health management solutions marketplace. Prior to OptumHealth, he worked for two years at OptumInsight as a Product Marketing Director, and six years at UnitedHealthCare in a combination of sales, business development and strategic marketing roles. Kading earned his BA and MBA from the University of St. Thomas and has been involved in health policy groups throughout the Minneapolis area and actively involved in the discussion around health reform strategies.

About DesignWise Medical:
DesignWise Medical is a unique, volunteer-based, nonprofit pediatric medical device organization that develops device-based solutions to children's unmet medical needs. With its partners - pediatric clinicians, parents, sponsors, volunteers, students and technology companies - DesignWise Medical identifies, develops and delivers collaborative solutions to an under served population. The company is leveraging its unique business model to change the dynamics of the children's medical device landscape by developing pediatric medical devices at a fraction of the cost of traditional product development.

For more information, visit: http://www.designwisemedical.org .

- RSS news feed for DesignWise Medical:
http://send2pressnewswire.com/author/designwise-medical-inc/feed .

NEWS SOURCE: DesignWise Medical Inc
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2011 Neotrope® News Network - all rights reserved.

TAGS: DesignWise Medical Inc, Devices and Research, Send2Press. ]]> http://www.send2press.com/newswire/2011-01-0111-004.shtml Wed, 12 Jan 2011 00:29:31 GMT NonProfit Medical Minneapolis Minnesota Send2Press Newswire http://www.send2press.com/newswire/2011-01-0111-004.shtml DesignWise Medical Inc. MINNEAPOLIS, Minn., Jan. 11 (SEND2PRESS NEWSWIRE) -- DesignWise Medical, a growing nonprofit pediatric medical device organization, announced today that it has added three new members to its board. With the addition of Tom McGoldrick, Ann Johnson and Jim Hartman, the DesignWise Medical Board of Directors has grown to six members, joining current board members, Jodi Raus, Alec Johnson and Brad Slaker.

"I am extremely excited and humbled to have these three very accomplished individuals join our board. As we move from a 'proof-of-concept' business to a 'fully-implemented' one, I am very confident that our newly expanded board will be invaluable in ensuring we are prepared for long-term success," said DesignWise Medical's founder and Chairman Brad Slaker.

Ann Johnson is the director of the Center for Nonprofit Management in the Opus College of Business at the University of St. Thomas. She has 30 years of nonprofit leadership and management experience in addition to expertise in professional training and curriculum development. She has served as an executive for health care, education, advocacy and grassroots organizations. In addition to her director of research and public policy role, Ann is the director of the Institute for Executive Director Leadership cohort for nonprofit executives. She also is a recognized speaker and presenter offering keynote presentations and training seminars nationally, regionally, and locally with a focus on board and executive development and nonprofit effectiveness.

Jim Hartman served as the chief executive of Enpath Medical, Inc. and its predecessor company, MedAmicus, Inc., from 1994 to his retirement in January 2006. He served as board chairman from 1994 to 2007, at which time the company was sold. He also served as chief financial officer from 1991 until his retirement. Enpath developed and manufactured medical devices for the vascular and cardiology markets. Jim serves on the board of two publicly traded companies, NVE Corp, and WSI Industries, Inc. He has an MBA from the University of St. Thomas and is a non-practicing CPA.

Tom McGoldrick served as chief executive officer of Monteris Medical Inc. from November 2002 until he retired in November 2005. He has been in the medical device industry for over 30 years and was cofounder and CEO of Fastitch Surgical in 2000. Fastitch (Now Incisive Medical) was a startup medical device company with unique technology in surgical wound closure. Prior to Fastitch, Tom was President and CEO of Minntech, a medical device company offering services for the dialysis, filtration, and separation markets. Prior to employment at Minntech, he held senior marketing, business development and international positions at Medtronic, Cardiac Pacemakers, Inc. and Johnson & Johnson. Tom is on the board of directors of two other startup medical device companies.

One of the first activities of the newly expanded board will be implementing DesignWise Medical's Charter Campaign, a one-time sponsorship opportunity for individuals and organizations to join DesignWise Medical in developing appropriate medical devices for children. During the campaign drive, new sponsors will become permanent charter members of the DesignWise Medical legacy. The charter campaign is open from January 1, 2011 thru May 31, 2011.

Additional information on the current DesignWise Medical Board of Directors, as well as key volunteers, can be obtained by contacting Brad Slaker, Founder, and CEO at: 612-385-2015 or brad.slaker@designwisemedical.org. You may also visit our website at: www.designwisemedical.org .

About DesignWise Medical:
DesignWise Medical is a unique volunteer-based nonprofit pediatric medical device organization focused on developing solutions to children's unmet medical needs. Through the sustained involvement of pediatric clinicians, parents, sponsors, volunteers and students we are able to identify, create and deliver collaborative solutions to an under served population. DesignWise Medical lies within the heart of the world-renowned medical device industry of the Upper Midwest with access to the regions highly regarded children's hospitals and engineering and technical schools. DesignWise Medical is committed to changing the dynamics of the children's medical device landscape by facilitating the collaboration of volunteer and philanthropic resources enabling us to develop pediatric medical devices at a fraction of the cost of the traditional approach to product development. By removing the predominant, financial barrier, we can ensure appropriate medical devices get made for children that need them.

- RSS news feed for
http://send2pressnewswire.com/author/designwise-medical-inc/feed .

NEWS SOURCE: DesignWise Medical Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2011 Neotrope® News Network - all rights reserved.

TAGS: DesignWise Medical Inc., Devices and Research, Send2Press. ]]> http://www.send2press.com/newswire/2010-10-1028-002.shtml Thu, 28 Oct 2010 13:10:52 GMT Medical Bethlehem Pennsylvania Send2Press Newswire http://www.send2press.com/newswire/2010-10-1028-002.shtml HoverTech International, Inc. BETHLEHEM, Pa. (SEND2PRESS NEWSWIRE) -- HoverTech International, Inc. (www.hovermatt.com), the leading manufacturer of lateral patient air transfer systems today announced the introduction of their new Model HTAIR® 1200 Air Supply to be used in conjunction with the HoverMatt® Air Transfer System for safe patient handling.

The HoverMatt® Air Transfer System has been used extensively to assist caregivers in the lateral transfer and repositioning of patients anywhere in the hospital. When used, this system has been proven to dramatically reduce back injuries to staff caused by lateral patient transfers.

After the patient is placed on the HoverMatt® transfer mattress, low pressure air from the air supply is used to inflate the mattress and, at the same time, escape from small holes on the underside of the transfer mattress.The escaping air acts as a lubricant to reduce friction which facilitates effortless transfers. The HoverMatt® Air Transfer System is available in multiple styles and sizes to accommodate any patient weight, and is ideally suited for the transfer of bariatric patients.

The new Model HTAIR® 1200 Air Supply has unique air flow control features which, until now, have never been available for air transfer systems. It offers a choice of two continuous air flow rates based on the size of the transfer mattress being used. In addition, it offers four adjustable air flow rate/pressure settings, which allows for easier, more controlled inflation of smaller positioning devices.

"This unique variable air control feature has never before been available on patient transfer system air supplies," said Dave Davis, the company President and CEO. "It is just another user-friendly advancement in a long line of innovations that continue to set HoverTech apart from the competition."

The new Model HTAIR® 1200 is a single unit that can cover all applications. It is designed to replace both the Models AIR200G and AIR400G air supplies, which have been used up to now. It is UL Classified to conform to Standard 60601-1. For more information go to: www.hovermatt.com/airSupply.

About HoverTech International, Inc.:
Based in Bethlehem, PA, HoverTech is a leader in providing the healthcare industry with easier patient transfer and repositioning, resulting in a safer environment for both the caregiver and the patient. Besides the HoverMatt® products, HoverTech offers a complete line of patient transfer chairs and lifts, and the unique HoverJack® for air-inflated vertical patient lifting.

- Image 72dpi: www.Send2PressNewswire.com/image/10-1027-hovermt_72dpi.jpg .

- Image Caption: HoverTech's New HTAIR 1200 Variable Flow Air Supply.

NEWS SOURCE: HoverTech International, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.

TAGS: HoverTech International, Inc., Devices and Research, Send2Press. ]]> http://www.send2press.com/newswire/2010-10-1019-002.shtml Tue, 19 Oct 2010 06:59:48 GMT Medical Dallas Texas Send2Press Newswire http://www.send2press.com/newswire/2010-10-1019-002.shtml Estill Medical Technologies, Inc. DALLAS, Texas, Oct. 19 (SEND2PRESS NEWSWIRE) -- Estill Medical Technologies, Inc., the creator of the Thermal Angel Blood and IV Fluid Infusion Warmer, announced this week its plans to distribute its fluid warming product line through Progressive Medical International (PMI).

The Thermal Angel, an in-line, battery-powered disposable, lightweight and completely portable blood and IV fluid warming device, is capable of intravenous application and irrigation warming. It can be used to help prevent fluid-induced hypothermia.

"We are excited to move forward with PMI," says Jay Lopez, president and CEO for Estill Medical Technologies, Inc. "They will be our first distributor for the EMS ground and flight service space. Until now, our focus has been on meeting U.S. military demand, so moving into commercial markets is an exciting step for the company."

Lopez adds that, "PMI is an outstanding distributor in this market, and we are looking forward to explosive growth with their team."

PMI is equally excited about the new relationship.

"We are very happy to be the first distributor to provide IV fluid infusion warming for the EMS industry," says Mirela Sabanovic-Lewis of PMI. "The Thermal Angel will be a great addition to our large selection of EMS products."

About PMI:
Founded in 1992, PMI (www.progressivemed.com) is a leading source for medical equipment and EMS supplies specifically tailored to meet the needs of surgery centers, clinics, emergency medical providers, air medical and military medical.

About Estill Medical Technologies, Inc.:
Estill Medical Technologies, Inc. was recently awarded the "Outstanding Military Product of the Year" by the Institute for Defense and Government Advancement for the Thermal Angel Blood and IV Fluid Infusion Warmer. The product is a patented medical device that is used in military and government; hospital and pre-hospital settings; EMS; flight service; fire; field; and more.

For more information, visit: www.thermalangel.com.

- Estill Medical news RSS feed:
http://send2pressnewswire.com/topics/estill-medical-technologies-inc/feed .

NEWS SOURCE: Estill Medical Technologies, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.

TAGS: Estill Medical Technologies, Inc., Devices and Research, Send2Press. ]]>